Patent intelligence · US
US 7105558
Gastrin and cholecystokinin receptor lignads (iv)
Gastrin and cholecystokinin receptor lignads (iv)
Patent details — US 7105558
- Jurisdiction
- US
- Status
- granted
- Grant date
- Sep 12, 2006
- Expiration
- Sep 7, 2026
- Applicant
- The James Black Foundation Limited
- Claims
- 31
- CPC classes
- A61K, A61K31/4192, A61K45/06, A61P
Quick answer
US 7105558 (Gastrin and cholecystokinin receptor lignads (iv)) is held by The James Black Foundation Limited. Status: granted. Granted Sep 12, 2006. Expires Sep 7, 2026 (0 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- The James Black Foundation Limited
- Grant date
- Expiration
- Claims
- 31
- CPC classes
- A61K, A61K31/4192, A61K45/06, A61P, A61P1/04
More from The James Black Foundation Limited
Related pharmaceutical patents in our USPTO index.
-
US 12343394
CD38 modulating antibody agents
granted -
US 12325699
Antibacterial compounds
granted -
US 12304964
CD38 modulating antibody
granted -
US 12187754
LpxC inhibitors and uses thereof
granted -
US 12161717
CD38 modulating antibody agents
granted -
US 12162949
CD38 antibody
granted -
US 11897873
Kappa opioid receptor antagonists and products and methods related thereto
granted -
US 11780930
CD38 modulating antibody
granted
Frequently asked questions
What is US patent 7105558?
US 7105558 (Gastrin and cholecystokinin receptor lignads (iv)) is held by The James Black Foundation Limited. Status: granted. Granted Sep 12, 2006. Expires Sep 7, 2026 (0 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 7105558?
The James Black Foundation Limited is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 38 pharmaceutical patents for this assignee.
When does US 7105558 expire?
Our index shows an expiration date of Sep 7, 2026 (0 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.